Spacers are used by people with respiratory diseases who have problems using MDIs (metered dose inhalers). This study used fluticasone propionate/salmeterol to look at the pharmacokinetic profiles produced by different spacers in their washed and un-washed states.
A randomised, open label, five-way crossover study to assess the systemic exposure of fluticasone propionate and salmeterol from SERETIDE™/ADVAIR™ 250 HFA MDI without spacer and with AeroChamber-Max spacer and VOLUMATIC™ both in their washed and unwashed states in adult subjects with mild or intermittent asthma.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
GSK Investigational Site
Wellington, New Zealand
The pharmacokinetic profile of fluticasone propionate (in particular the area under the curve to time t and the maximum concentration)
The pharmacokinetic profile of salmeterol and the time to maximum concentration of fluticasone propionate
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.